KFD Bio is focusing on development of oral enzymes which is characterized with gastro-tolerant novel drugs. 

The lead compound TRA16, First-in-disease is designed to effectively degrade oxalate from food in the upper GI-tract, lower the level of urinary oxalate and prevent oxalate crystals in kidney. Currently TRA16 completed phase 2 clinical trial in secondary hyperoxaluria patients and has record-breaking results. We believe that TRA16 will be the 1st approval drug for 3 million secondary hyperoxaluria patients in US.

Our second compound, another oral enzyme DOS01 First-in-disease is designed to dissolve kidney stones. The early human data addressed that, one third of dozens kidney stones patients were observed that 50% volume reduction of at least one stone after 3-month treatment.